RT Journal Article
T1 The immunomodulator dimethyl itaconate inhibits several key steps of angiogenesis in cultured endothelial cells
A1 Vidal-Valenzuela, Isabel
A1 Fernández-Florido, Elena
A1 Marrero-Capitán, Ana Dácil
A1 Castilla-Ruiz, Laura
A1 Rodríguez-Quesada, Ana María
A1 Martínez-Póveda, Beatriz Amparo
A1 Medina-Torres, Miguel Ángel
K1 Neovascularización
K1 Inmunomoduladores
AB The dimethyl derivative of the immunomodulator itaconate has been previously shown to have anti-inflammatory, anti-oxidative, and immunomodulatory effects. In the present work, we evaluate the potential of dimethyl itaconate as an anti-angiogenic compound by using cultured endothelial cells and several in vitro assays that simulate key steps of the angiogenic process, including endothelial cell proliferation, migration, invasion, and tube formation. Our results show that dimethyl itaconate interferes with all the previously mentioned steps of the angiogenic process, suggesting that dimethyl itaconate behaves as an anti-angiogenic compound.
PB MDPI
YR 2022
FD 2022
LK https://hdl.handle.net/10630/36578
UL https://hdl.handle.net/10630/36578
LA eng
NO Vidal, I.; Fernández-Florido, E.; Marrero, A.D.; Castilla, L.; R. Quesada, A.; Martínez-Poveda, B.; Medina, M.Á. The Immunomodulator Dimethyl Itaconate Inhibits Several Key Steps of Angiogenesis in Cultured Endothelial Cells. Int. J. Mol. Sci. 2022, 23, 15972. https://doi.org/10.3390/ ijms232415972
NO Partial funding for open access charge: Universidad de MálagaThis research was funded by grants PID2019-105010RB-I00 (MICINN and FEDER), UMA18FEDERJA-220 and PY20_00257 (Andalusian Government and FEDER), and funds from group BIO 267 (Andalusian Government). The “CIBER de Enfermedades Raras” and “CIBER de Enfermedades Cardiovasculares” are initiatives from the ISCIII (Spain).
DS RIUMA. Repositorio Institucional de la Universidad de Málaga
RD 3 mar 2026